EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study

Mingfen Lai, Shuai Li, Zhongwen Jin, Mingzhang Chang, Fangming Li, Peixin Yang, Yiming He, Qinhua Zhang

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04100-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Mingfen Lai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Jiangmen Central Hospital, Jiangmen, 529000, Guangdong Province, China. Hauptthemen laut MEDLINE: Nasopharyngeal Carcinoma, Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, Chemoradiotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: We aimed to retrospectively evaluate the safety and efficacy of tislelizumab combined with the gemcitabine and cisplatin (GP) regimen as neoadjuvant therapy followed by nimotuzumab with concurrent chemoradiotherapy (CCRT) for locoregionally advanced nasopharyngeal carcinoma (LANPC). PATIENTS AND METHODS: From March 2021 to January 2022, 44 patients were included in our hospital. Tislelizumab and the GP regimen were given every three weeks for 1-4 cycles, followed by nimotuzumab with chemoradiotherapy, which included lobaplatin and intensity-modulated radiation therapy (IMRT). All patients were analyzed for tumor response at regular intervals during induction therapy, chemoradiotherapy, and follow-up visits. RESULTS: Forty-one (93%) patients completed 4 cycles of GP and tislelizumab during neoadjuvant treatment. Forty-one patients (93%) finished two cycles of lobaplatin treatment, and forty-two patients (95%) finished six weeks of nimotuzumab treatment during concurrent chemoradiotherapy. Of the patients, twenty (46%) had a complete response, and twenty-four (55%) had a partial response prior to CCRT. After chemoradiotherapy, 91% of patients (40 out of 44) and 98% of patients (43 out of 44) had complete responses, respectively, at three and six months. With 34 months of median follow-up time, overall survival and progression-free survival were not reached. The 2-year overall survival rate was 93% (95% CI, 0.803-0.977), and the 2-year progression-free survival rate was 91% (95% CI, 0.776-0.965). Of the patients, 43% had treatment-related adverse events, and 9.1% had immune-related adverse events (irAEs) from grades 3-4. CONCLUSION: Tislelizumab plus induction chemotherapy followed by nimotuzumab with chemoradiotherapy significantly improved tumor response, superior progression-free survival, and manageable safety for high-risk LANPC. However, our study demonstrates the potential benefits of combining nimotuzumab with chemoradiotherapy after neoadjuvant chemotherapy in high-risk LANPC patients; the findings are preliminary and must be validated by larger, more rigorously designed trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal CarcinomaAntibodies, Monoclonal, HumanizedNeoadjuvant TherapyChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsNasopharyngeal NeoplasmsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultGemcitabineDeoxycytidineCisplatinAgedNeoplasm StagingOrganoplatinum Compounds

Stichwörter der Autor:innen

Concurrent chemoradiotherapyLocoregionally advanced nasopharyngeal carcinomaNeoadjuvant therapyNimotuzumabTislelizumab

Substanzen

Antibodies, Monoclonal, HumanizednimotuzumabGemcitabineDeoxycytidinetislelizumabCisplatinOrganoplatinum Compounds

Autor:innen und Institutionen

  • Department of Oncology, Jiangmen Central Hospital, Jiangmen, 529000, Guangdong Province, China.
  • Department of Otorhinolaryngology, Head and Neck Surgery, Jiangmen Central Hospital, Jiangmen, 529000, Guangdong Province, China.
  • Department of Otorhinolaryngology, Taishan People's Hospital, Taishan, 529200, Guangdong Province, China.
  • Department of Otorhinolaryngology, Enping People's Hospital, Enping, 529499, Guangdong Province, China.
  • Department of Oncology, Jiangmen Central Hospital, Jiangmen, 529000, Guangdong Province, China. 459208644@qq.com.

Zitieren

APA

Lai, M., Li, S., Jin, Z., Chang, M., Li, F., Yang, P., He, Y., & Zhang, Q. (2025). Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04100-5

Vancouver

Lai M, Li S, Jin Z, Chang M, Li F, Yang P, et al. Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04100-5

BibTeX
@article{Lai2025,
  author = {Lai, Mingfen and Li, Shuai and Jin, Zhongwen and Chang, Mingzhang and Li, Fangming and Yang, Peixin and He, Yiming and Zhang, Qinhua},
  title = {Tislelizumab and GP regimen neoadjuvant therapy followed by concurrent chemoradiotherapy with nimotuzumab in patients with stage IVA nasopharyngeal carcinoma: a retrospective study},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04100-5}
}
Kostenlos starten →